BERLIN & MONTREAL, August 31, 2020 (Newswire.com) - Eckert & Ziegler Radiopharma GmbH and Jubilant Radiopharma, a wholly-owned unit of Jubilant Pharma Limited, signed an agreement for the exclusive distribution of Eckert & Ziegler’s proprietary generator “GalliaPharm®” in Canada by Jubilant Radiopharma to meet the growing demand of this unique product.
GalliaPharm® has recently been approved by Health Canada for in-vitro radiolabeling of carrier molecules for diagnostic procedures using positron emission tomography (PET). This major advance for specialists in nuclear medicine and functional molecular medical imaging will allow for the labelling of molecular vectors used in the diagnosis of neuroendocrine cancers, which are particularly difficult to detect early. It is also used for the clinical development of other molecular vectors such as in the diagnosis of prostate cancer (recurrent forms), the most common cancer in men.
GalliaPharm® is a closed system consisting of pharmacopoeia grade borosilicate glass column containing a titanium dioxide bed on which 68Ge is adsorbed. 68Ga is continuously produced by decay of its radioactive parent 68Ge and is eluted with sterile ultrapure 0,1 mol/l hydrochloric acid. GalliaPharm® is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi). It is registered as a medicinal product in 17 European countries. Eckert & Ziegler Radiopharma GmbH is also a holder of a Type II Drug Master File (#28741) in the USA.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Dr. Harald Hasselmann, member of the executive board and responsible for the business segment Medical stated, “We are pleased to have received the Notice of Compliance from Health Canada for GalliaPharm®. Canada is an important market and with the approval, we are able to answer the growing demand for 68Ga-based diagnostics. We are very happy that, with Jubilant Radiopharma, we have found a local partner who provides both, highest expertise in radiopharmaceuticals and a strong network of specialists to satisfy our customers.”
Sergio Calvo, President of Jubilant Radiopharma’s Radiopharmaceuticals Division, stated, “Eckert & Ziegler’s GalliaPharm® is an excellent addition to our PET portfolio, which includes RUBY-FILL® for advanced myocardial perfusion imaging. GalliaPharm® will provide expanded access of PET in Canada and will enhance the way patients with known neuroendocrine cancers are both diagnosed and managed.”
“This agreement is another landmark event for Jubilant Radiopharma, supporting its ongoing commitment to the global expansion and utility of nuclear medicine and PET imaging. Our goal is to grow SPECT and PET imaging globally by providing products that enable physicians to deliver high quality diagnostic studies as part of our mission of Improving Lives through Nuclear Medicine,” stated Pramod Yadav, CEO Jubilant Pharma Limited.